Document Detail

The effect of a selenium supplementation on the outcome of patients with severe systemic inflammation, burn and trauma.
MedLine Citation:
PMID:  11568457     Owner:  NLM     Status:  MEDLINE    
Patients with systemic inflammatory response syndrome (SIRS) and sepsis exhibit decreased plasma selenium and glutathione peroxidase activity. This has been shown in several clinical studies. Moreover, the degree of selenium deficiency correlates with the severity of the disease and the incidence of mortality. Patients with SIRS and sepsis are exposed to severe oxidative stress. Selenoenzymes play a major role in protecting cells against peroxidation, especially lipid peroxidation and are involved in the regulation of inflammatory processes. Therefore, selenium substitution in those patients might be effective in the prevention of multiorgan failure. The results of randomised clinical trials investigating selenium substitution in critical ill patients with inflammation are reviewed. In two independently performed randomised, prospective clinical trials, including patients with systemic inflammatory response syndrome or sepsis, the supplementation of selenium revealed a significant reduction in multiorgan failure and, especially, a lower incidence of acute renal failure and respiratory distress syndrome. One of those trials also could demonstrate a significant reduction of mortality in the most severely ill patients. Two other studies, where selenium together with other trace elements or a mixture of antioxidants were used in the treatment of patients with severe burn injuries or trauma showed a significant reduction in the secondary infection rate, including sepsis. Thus, selenium supplementation seems to improve the outcome of patients with SIRS, sepsis and severe injury, however, pivotal prospective clinical trials with sufficient statistical power are now necessary to finally prove the efficacy of a selenium supplementation in these diseases.
R Gärtner; W Albrich; M W Angstwurm
Related Documents :
6476597 - Evaluation of a low-flow oxygen-conserving nasal cannula.
21525937 - Oxidative stress and erk1/2 phosphorylation as predictors of outcome in hepatocellular ...
8052817 - Plasmapheresis in the treatment of primary septic shock in humans.
19681767 - N-3 fatty acid supplementation in burned paediatric patients.
23023467 - Acute encephalopathy with pandemic (h1n1) 2009 virus infection.
20307437 - Association of abnormal foot angles and onychocryptosis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  BioFactors (Oxford, England)     Volume:  14     ISSN:  0951-6433     ISO Abbreviation:  Biofactors     Publication Date:  2001  
Date Detail:
Created Date:  2001-09-24     Completed Date:  2001-11-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8807441     Medline TA:  Biofactors     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  199-204     Citation Subset:  IM    
Klinikum der Ludwig-Maximilians-Universität München, Medizinische Klinik- Innenstadt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Burns / drug therapy*
Clinical Trials as Topic
Dietary Supplements
Selenium / administration & dosage,  therapeutic use*
Systemic Inflammatory Response Syndrome / drug therapy*
Treatment Outcome
Wounds and Injuries / drug therapy*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Selenium (Se) from high-selenium broccoli is utilized differently than selenite, selenate and seleno...
Next Document:  Glutathione peroxidase and viral replication: implications for viral evolution and chemoprevention.